Hot Stocks

The stock market changes from minute to minute, and what’s hot today may not be hot tomorrow. Our expert analysts spot hot stocks that are heating up before the crowd swoops in to bid prices higher, and our journalists sift through the noise to shine a light on trending investments -- in spaces ranging from quantum computing to marijuana stocks -- to determine whether they’re actually worth your time.

Shorts Are Piling Onto These 3 Companies

By Tom Taulli, InvestorPlace Contributor
A shaky earnings season could be good news for the shorts. Here are three companies really getting the stink-eye from investors right now.

Grading 6 Defense Contractors After the Farnborough Air Show

By Susan J. Aluise, Aviation, Auto & Transportation Writer
Looming defense cuts mean investors have to chose carefully. Here's how the sector's top players stack up now that the results of this year's air show are in.

Cure TV’s Nuttiness With a la Carte Pricing

By Jonathan Berr, InvestorPlace Contributor
Industry battles over carriage fees, such as the Dish-Viacom brawl, mask a bigger issue. Why should consumers pay for channels they don't want?

9 Biotech Buyout Players to Watch

By Jeff Reeves
The deal between Human Genome Sciences and GlaxoSmithKline is just the most recent of big pharma buyouts -- and these biotech players could be next.

Retail Results Spoil the Day — Monday’s IP Market Recap

By Marc Bastow, InvestorPlace Assistant Editor
A disappointing retail report and mixed results for Citigroup's second quarter weighed on markets Monday, though M&A news sparked life into pharma.

Gold, Silver Lack Luster on Monday

By Angela Nazworth, InvestorPlace Writer
Gold futures traded flat and silver showed marginal losses Monday as investors wait for Bernanke to speak this week in Washington.

HGSI Holdout Proves Profitable — for Bagels

By Marc Bastow, InvestorPlace Assistant Editor
Joint pharmaceutical developers Human Genome and GlaxoSmithKline agreed to a sweetened $14.25/share offer for HGSI, cheering Rockville-area diners.

Citigroup: Too Big to Grow?

By Dan Burrows, InvestorPlace Feature Writer
Yes, its balance sheet is stronger, and the worst may be over. But the bank's global sprawl is hampering revenue and profits, and it's hard to see past that.

GlaxoSmithKline to Pay $3.6B for Human Genome Sciences

By Christopher Freeburn, InvestorPlace Writer
GlaxoSmithKline will pay $14.25 a share, a total of $3.6 billion, to acquire its long-term research partner Human Genome Sciences.

MasterCard and Visa Agree to $6B Fee Settlement

By Christopher Freeburn, InvestorPlace Writer
Under a proposed settlement with retailers, Mastercard, Visa and a number of banks will pay more than $6 billion and will cut processing fees for eight months.

The Target-Neiman Marcus Partnership Looks Like a Winner

By Will Ashworth, InvestorPlace Contributor
The odd-sounding partnership with Neiman Marcus makes a lot more sense than people realize. Here's why it may be a savvy move for both retailers.

Merck Could Have a Home Run in Sight

By James Brumley, InvestorPlace Feature Writer
Merck’s new drug odanacatib can be thanked for the stock's recent rally, but there are two questions that need to be answered.

Gold, Silver Climb to End Dismal Week on a High Note

By Angela Nazworth, InvestorPlace Writer
Gold and silver futures closed sharply higher on Friday. Gold bullion showed significant gains as well.

Wells Fargo’s Record Profits Show Housing on the Mend

By Dan Burrows, InvestorPlace Feature Writer
Wells Fargo posted all-time high quarterly profits thanks to better results in mortgages and retail banking -- good news for WFC, and for the market.

All Aboard the Bakken Shale Railroad Plays

By Aaron Levitt, InvestorPlace Contributor
The ever-growing need to move drilling material in and crude oil out by rail is creating a gusher of revenue for a select group of railroad companies.

JPMorgan Has a Cold, Not Pneumonia

By Dan Burrows, InvestorPlace Feature Writer
JPMorgan Chase's second-quarter earnings and Friday's rally prove that everything is relative to expectations -- at least in the daily scrum of trading.

JPMorgan Profit Tops Forecasts, Despite Trading Losses

By Christopher Freeburn, InvestorPlace Writer
JPMorgan Chase shook off trading losses to report Q2 earnings of $1.21, surprising Wall Street, which was looking for 70 cents.

Don’t Buy Into Big Banks’ Hooey

By Marc Bastow, InvestorPlace Assistant Editor
JPMorgan announced a plan to claw back monies from executives in the wake of what is now a $5 billion loss on trading. It's not a remedy -- it's a smug snub.

Look What’s Up When the Market’s Are Down

By Richard Band
Despite a down day Thursday consumer, pharmaceutical and utility ETF's did very well and investors may want to look at the sectors for investment
Load More Articles